Compare BridgeBio Pharma Inc (BBIO) vs Coursera Inc (COUR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Coursera Inc — how do they compare? BridgeBio Pharma Inc trades at $84.99 (market cap $16.36B), while Coursera Inc trades at $5.65 (market cap $1.50B). The key difference: BridgeBio Pharma Inc is far larger — about 10.9× Coursera Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | COUR | |
|---|---|---|
Market Cap | $16.36B | $1.50B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $12.20 |
52-Week Low | $47.29 | $5.09 |
Enterprise Value | $18.14B | $759.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.64, down 1.22% on the day, with a bullish technical signal from moving averages and strong analyst support. Revenue surged to $502.08M in 2025, though net losses widened to -$724.93M, reflecting high R&D spending. Recent news highlights Q2 2026 earnings misses but revenue beats, driven by Attruby sales growth and three late-stage regulatory submissions expected by mid-2027.
Outlook remains optimistic with an 88% buy rating and $104.56 price target, but risks include persistent cash burn, high debt of $1.72B, and negative equity. Key catalysts are FDA decisions in 2027, with success potentially driving significant upside, though failure could exacerbate financial strain.
Coursera (COUR) trades at $5.575, down 3.21% today, with a bearish technical signal and mixed earnings performance. Revenue growth continues with 2025 reaching $757.5M, though the company remains unprofitable with a -15.39% net margin. Recent Q2 2026 earnings beat expectations at $0.17 per share versus $0.10 expected. Analyst sentiment is positive with 53% buy ratings and a $7.70 consensus price target representing 38% upside potential.
The stock offers growth exposure to online education but faces profitability challenges. Upside catalysts include continued revenue expansion and strategic AI investments, while risks include persistent losses and competitive pressures. Wall Street sees significant undervaluation despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
